PH12015502708A1 - Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis - Google Patents
Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesisInfo
- Publication number
- PH12015502708A1 PH12015502708A1 PH12015502708A PH12015502708A PH12015502708A1 PH 12015502708 A1 PH12015502708 A1 PH 12015502708A1 PH 12015502708 A PH12015502708 A PH 12015502708A PH 12015502708 A PH12015502708 A PH 12015502708A PH 12015502708 A1 PH12015502708 A1 PH 12015502708A1
- Authority
- PH
- Philippines
- Prior art keywords
- methods
- phosphate receptor
- chiral synthesis
- compounds
- receptor modulators
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 230000015572 biosynthetic process Effects 0.000 title abstract 2
- 238000003786 synthesis reaction Methods 0.000 title abstract 2
- 229940127530 Sphingosine 1-Phosphate Receptor Modulators Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 abstract 2
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 abstract 2
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
- A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/12—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom
- C07C245/14—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Pest Control & Pesticides (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Agronomy & Crop Science (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26130109P | 2009-11-13 | 2009-11-13 | |
| US26247409P | 2009-11-18 | 2009-11-18 | |
| PCT/US2010/056760 WO2011060392A1 (en) | 2009-11-13 | 2010-11-15 | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12015502708B1 PH12015502708B1 (en) | 2016-10-17 |
| PH12015502708A1 true PH12015502708A1 (en) | 2016-10-17 |
Family
ID=43992106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12015502708A PH12015502708A1 (en) | 2009-11-13 | 2015-12-04 | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
Country Status (30)
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3868377A1 (en) | 2009-11-13 | 2021-08-25 | Receptos Llc | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| KR101781233B1 (ko) | 2009-11-13 | 2017-09-22 | 셀진 인터내셔널 Ii 에스에이알엘 | 스핑고신 1 포스페이트 수용체 조절자 및 카이랄 합성 방법 |
| US9481659B2 (en) | 2011-05-13 | 2016-11-01 | Celgene International Ii Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| NZ702974A (en) * | 2012-06-21 | 2016-03-31 | Eisai R&D Man Co Ltd | Novel indanesulfamide derivative |
| WO2014158302A1 (en) * | 2013-03-25 | 2014-10-02 | Swenson Rolf Eric | Novel sphingosine 1-phosphate receptor antagonists |
| WO2015066515A1 (en) * | 2013-11-01 | 2015-05-07 | Receptos, Inc. | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
| CA2981743A1 (en) | 2015-04-06 | 2016-10-13 | Auspex Pharmaceuticals, Inc. | Deuterium-substituted oxadiazoles |
| US11111223B2 (en) | 2016-06-14 | 2021-09-07 | Receptos Llc | Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof |
| US11192886B2 (en) | 2016-07-22 | 2021-12-07 | Medshine Discovery Inc. | S1P1 agonist and application thereof |
| CN109563059A (zh) * | 2016-08-19 | 2019-04-02 | 苏州科睿思制药有限公司 | 奥扎莫德的晶型及其制备方法 |
| EP3508481A4 (en) * | 2016-09-14 | 2019-07-10 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | CRYSTALLINE FORM OF OZANIMOD HYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME |
| CN108137516A (zh) * | 2016-09-14 | 2018-06-08 | 杭州领业医药科技有限公司 | 奥扎莫德的晶型、其制备方法及药物组合物 |
| EP3518922A1 (en) * | 2016-09-29 | 2019-08-07 | Celgene International II Sarl | Compounds and methods for treating lupus |
| WO2018157813A1 (zh) * | 2017-02-28 | 2018-09-07 | 南京明德新药研发股份有限公司 | 螺环类化合物及其应用 |
| WO2018184185A1 (zh) * | 2017-04-07 | 2018-10-11 | 杭州领业医药科技有限公司 | 奥扎莫德加成盐晶型、制备方法及药物组合物和用途 |
| CN108727291A (zh) * | 2017-04-21 | 2018-11-02 | 宁波爱诺医药科技有限公司 | 奥扎莫德及其中间体的制备方法 |
| CN108727292A (zh) * | 2017-04-21 | 2018-11-02 | 宁波爱诺医药科技有限公司 | 一种奥扎莫德及其中间体的制备方法 |
| WO2018208855A1 (en) | 2017-05-08 | 2018-11-15 | Celgene International Ii Sarl | Sphingosine 1 phosphate receptor agonists for neuroprotection |
| CN110997645B (zh) * | 2017-05-22 | 2023-10-10 | 埃吉斯制药公司 | 奥扎尼莫德的制备方法 |
| US10660879B2 (en) | 2017-06-23 | 2020-05-26 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| CA3061201A1 (en) | 2017-06-23 | 2018-12-27 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| CN109280035B (zh) * | 2017-07-19 | 2023-06-09 | 广东东阳光药业有限公司 | 奥扎莫德的多晶型及其制备方法 |
| CN110944982A (zh) * | 2017-08-31 | 2020-03-31 | 苏州科睿思制药有限公司 | 奥扎莫德盐酸盐的晶型及其制备方法 |
| WO2019058290A1 (en) * | 2017-09-20 | 2019-03-28 | Suven Life Sciences Limited | IMPROVED PROCESS FOR THE PREPARATION OF AZANIMOD A-AMINO COMPOUND |
| WO2019094409A1 (en) | 2017-11-07 | 2019-05-16 | Teva Pharmaceuticals International Gmbh | Salts and solid state forms of ozanimod |
| CN107857760A (zh) * | 2017-11-21 | 2018-03-30 | 南京天翔医药科技有限公司 | 鞘氨醇‑1‑磷酸受体调节剂及其应用 |
| JP2021511375A (ja) * | 2018-01-18 | 2021-05-06 | シージャーヂュアン・サガシティー・ニュー・ドラッグ・デヴェロップメント・カンパニー・リミテッド | 三環式化合物の結晶形、塩形及びその製造方法 |
| EP3769759B1 (en) | 2018-03-20 | 2023-11-15 | Eisai R&D Management Co., Ltd. | Combination of an indanesulfamide derivative with perampanel for use in the treatment of epilepsy |
| CN110615747A (zh) * | 2018-06-20 | 2019-12-27 | 广东东阳光药业有限公司 | 一种二氢茚中间体的制备方法 |
| CN112771028A (zh) | 2018-09-12 | 2021-05-07 | 细胞制药有限公司 | 用于制备奥扎莫德及其中间体(s)-1-氨基-2,3-二氢-1h-茚基-4-甲腈的方法 |
| AR116479A1 (es) * | 2018-09-25 | 2021-05-12 | Quim Sintetica S A | Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios |
| US11390593B2 (en) | 2018-12-07 | 2022-07-19 | Synthon B.V. | Process for preparing ozanimod |
| US20220144788A1 (en) * | 2019-03-29 | 2022-05-12 | Receptos Llc | Sphingosine 1 phosphate receptor modulators |
| WO2020205481A1 (en) * | 2019-03-29 | 2020-10-08 | Celgene International Ii Sarl | Sphingosine 1 phosphate receptor modulators |
| WO2020205483A1 (en) * | 2019-03-29 | 2020-10-08 | Celgene International Ii Sarl | Sphingosine 1 phosphate receptor modulators |
| EP3959204A4 (en) * | 2019-04-26 | 2022-12-28 | Receptos Llc | SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR |
| CN112062785B (zh) * | 2019-06-11 | 2023-06-27 | 广东东阳光药业有限公司 | 奥扎莫德及其中间体的制备方法 |
| US20220259163A1 (en) | 2019-07-16 | 2022-08-18 | Synthon B.V. | Improved process for preparing ozanimod |
| AU2020372647A1 (en) | 2019-10-31 | 2022-06-16 | Idorsia Pharmaceuticals Ltd | Combination of a CXCR7 antagonist with an S1P1 receptor modulator |
| AU2021205465A1 (en) * | 2020-01-06 | 2022-07-14 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| WO2021175223A1 (zh) * | 2020-03-04 | 2021-09-10 | 南京明德新药研发有限公司 | 苯并2-氮杂螺[4.4]壬烷类化合物及其应用 |
| WO2021175225A1 (zh) | 2020-03-04 | 2021-09-10 | 南京明德新药研发有限公司 | 三环类化合物及其应用 |
| US11554111B2 (en) * | 2020-03-17 | 2023-01-17 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of coronavirus infection |
| EP4126826A1 (en) | 2020-04-02 | 2023-02-08 | Synthon B.V. | Crystalline form of ozanimod hydrochloride |
| CN111620788B (zh) * | 2020-04-20 | 2022-09-30 | 广东莱佛士制药技术有限公司 | 一种制备(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法 |
| JP2024510647A (ja) * | 2021-04-09 | 2024-03-08 | ヒーリオイースト ファーマシューティカル カンパニー リミテッド | オキサジアゾール置換スピロ環系化合物とその使用 |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
| WO2023152767A1 (en) | 2022-02-11 | 2023-08-17 | Mylan Laboratories Limited | Polymorphic forms of ozanimod hydrochloride |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1479544A (en) | 1974-02-07 | 1977-07-13 | American Cyanamid Co | 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use |
| FR2628103B1 (fr) * | 1988-03-03 | 1991-06-14 | Roussel Uclaf | Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides |
| US5039802A (en) | 1990-04-18 | 1991-08-13 | Merck & Co., Inc. | Arylation process for preparation of chiral catalysts for ketone reduction |
| WO1992018462A1 (en) | 1991-04-12 | 1992-10-29 | Schering Corporation | Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase |
| GB2290790A (en) | 1994-06-30 | 1996-01-10 | Merck & Co Inc | Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes |
| KR100629672B1 (ko) * | 1998-01-23 | 2006-09-29 | 상꾜 가부시키가이샤 | 스피로피페리딘 유도체 |
| AR035585A1 (es) † | 2000-09-15 | 2004-06-16 | Pharmacia Corp | Derivados del acido 2-amino-2-alquil-4-heptenoico, composicion farmaceutica y su uso en la fabricacion de medicamentos |
| US20040058894A1 (en) | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
| AU2003297232B2 (en) * | 2002-12-20 | 2010-02-04 | Merck Sharp & Dohme Corp. | 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles |
| ES2624610T3 (es) | 2003-04-11 | 2017-07-17 | Ptc Therapeutics, Inc. | Compuestos de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades |
| US20070043014A1 (en) * | 2003-10-01 | 2007-02-22 | Merck & Co., Inc. | 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
| WO2005058848A1 (en) * | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| US20060173183A1 (en) | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
| WO2006120577A1 (en) | 2005-02-22 | 2006-11-16 | Teva Pharmaceutical Industries Ltd. | Improved process for the synthesis of enantiomeric indanylamine derivatives |
| KR100667075B1 (ko) | 2005-07-22 | 2007-01-10 | 삼성에스디아이 주식회사 | 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치 |
| US20080221126A1 (en) † | 2005-08-03 | 2008-09-11 | Atadja Peter W | Use of Hdac Inhibitors for the Treatment of Myeloma |
| CA2621949A1 (en) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| PE20070705A1 (es) * | 2005-11-25 | 2007-08-23 | Basf Ag | Compuestos de indanil - y tetrahidronaftil-amino-azolina para combatir pestes animales |
| CA2634488C (en) | 2005-12-21 | 2016-10-04 | Joseph Gabriele | Catecholamine regulated protein |
| US20090163482A1 (en) | 2006-03-13 | 2009-06-25 | Mchardy Stanton Furst | Tetralines antagonists of the h-3 receptor |
| US20080009534A1 (en) * | 2006-07-07 | 2008-01-10 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| RU2442780C2 (ru) * | 2006-09-21 | 2012-02-20 | Актелион Фармасьютиклз Лтд | Фенильные производные и их применение в качестве иммуномодуляторов |
| WO2008064320A2 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
| NZ577111A (en) | 2006-12-15 | 2012-05-25 | Abbott Lab | Novel oxadiazole compounds |
| JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| WO2008143729A2 (en) | 2007-02-28 | 2008-11-27 | Rib-X Pharmaceuticals, Inc. | Macrolide compounds and methods of making and using the same |
| GB0725104D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| US20090298894A1 (en) | 2008-04-21 | 2009-12-03 | Asahi Kasei Pharma Corporation | Amino acid compounds |
| PT2291080E (pt) * | 2008-05-14 | 2015-10-30 | Scripps Research Inst | Novos modelamodeladores dos recetores da esfingosina fosfato |
| WO2009151259A1 (ko) * | 2008-06-13 | 2009-12-17 | 두원공과대학교 | 로터리 밸브를 구비한 왕복동 압축기 |
| GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| WO2011005290A1 (en) | 2009-06-23 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders |
| GB0911130D0 (en) | 2009-06-26 | 2009-08-12 | Glaxo Group Ltd | Novel compounds |
| KR101781233B1 (ko) | 2009-11-13 | 2017-09-22 | 셀진 인터내셔널 Ii 에스에이알엘 | 스핑고신 1 포스페이트 수용체 조절자 및 카이랄 합성 방법 |
| EP3868377A1 (en) | 2009-11-13 | 2021-08-25 | Receptos Llc | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| DK2498609T3 (en) | 2009-11-13 | 2018-06-18 | Celgene Int Ii Sarl | SELECTIVE HETEROCYCLIC SPHINGOSIN-1 PHOSPHATRECEPTOR MODULATORS |
| US9481659B2 (en) | 2011-05-13 | 2016-11-01 | Celgene International Ii Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| EP2766020A4 (en) | 2011-10-12 | 2015-04-01 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD |
-
2010
- 2010-11-15 EP EP20215106.4A patent/EP3868377A1/en not_active Withdrawn
- 2010-11-15 ES ES18160667T patent/ES2858337T3/es active Active
- 2010-11-15 CA CA2780772A patent/CA2780772C/en active Active
- 2010-11-15 CA CA2986521A patent/CA2986521C/en active Active
- 2010-11-15 PL PL18160667T patent/PL3406142T3/pl unknown
- 2010-11-15 LT LTEP18160667.4T patent/LT3406142T/lt unknown
- 2010-11-15 AU AU2010319983A patent/AU2010319983B2/en active Active
- 2010-11-15 NO NO10830880A patent/NO2498610T3/no unknown
- 2010-11-15 DK DK10830880.0T patent/DK2498610T3/en active
- 2010-11-15 HU HUE10830880A patent/HUE037535T2/hu unknown
- 2010-11-15 EP EP18160667.4A patent/EP3406142B8/en active Active
- 2010-11-15 RS RS20180647A patent/RS57253B1/sr unknown
- 2010-11-15 JP JP2012539065A patent/JP5650233B2/ja active Active
- 2010-11-15 MX MX2012005560A patent/MX2012005560A/es active IP Right Grant
- 2010-11-15 PT PT108308800T patent/PT2498610T/pt unknown
- 2010-11-15 RS RS20210360A patent/RS61829B1/sr unknown
- 2010-11-15 PL PL10830880T patent/PL2498610T3/pl unknown
- 2010-11-15 EP EP10830880.0A patent/EP2498610B2/en active Active
- 2010-11-15 BR BR112012011427A patent/BR112012011427B8/pt active IP Right Grant
- 2010-11-15 EA EA201290323A patent/EA024801B1/ru not_active IP Right Cessation
- 2010-11-15 CN CN201510295907.XA patent/CN105061350B/zh active Active
- 2010-11-15 DK DK18160667.4T patent/DK3406142T3/da active
- 2010-11-15 MY MYPI2012002084A patent/MY161854A/en unknown
- 2010-11-15 KR KR1020167035297A patent/KR101752124B1/ko active IP Right Grant
- 2010-11-15 ES ES10830880.0T patent/ES2673160T3/es active Active
- 2010-11-15 SI SI201032063T patent/SI3406142T1/sl unknown
- 2010-11-15 MY MYPI2016002092A patent/MY189750A/en unknown
- 2010-11-15 LT LTEP10830880.0T patent/LT2498610T/lt unknown
- 2010-11-15 KR KR1020127015292A patent/KR101721716B1/ko active IP Right Grant
- 2010-11-15 NZ NZ599915A patent/NZ599915A/en unknown
- 2010-11-15 EA EA201690391A patent/EA035768B1/ru not_active IP Right Cessation
- 2010-11-15 HU HUE18160667A patent/HUE054000T2/hu unknown
- 2010-11-15 WO PCT/US2010/056760 patent/WO2011060392A1/en active Application Filing
- 2010-11-15 BR BR122018077504A patent/BR122018077504B8/pt active IP Right Grant
- 2010-11-15 CN CN201080061144.8A patent/CN102762100B/zh active Active
- 2010-11-15 TR TR2018/07912T patent/TR201807912T4/tr unknown
- 2010-11-15 SG SG10201407357PA patent/SG10201407357PA/en unknown
- 2010-11-15 PT PT181606674T patent/PT3406142T/pt unknown
- 2010-11-15 SI SI201031704T patent/SI2498610T1/en unknown
- 2010-11-15 US US12/946,819 patent/US8362048B2/en active Active
-
2012
- 2012-05-09 IL IL219691A patent/IL219691B/en active IP Right Grant
-
2013
- 2013-01-14 US US13/740,661 patent/US20130231326A1/en not_active Abandoned
- 2013-03-14 HK HK16100726.3A patent/HK1213874A1/zh unknown
- 2013-03-14 HK HK13103206.9A patent/HK1175948A1/xx unknown
- 2013-11-14 JP JP2013235966A patent/JP5982705B2/ja active Active
-
2014
- 2014-11-12 JP JP2014229895A patent/JP2015038145A/ja active Pending
-
2015
- 2015-02-26 US US14/632,675 patent/US9388147B2/en active Active
- 2015-12-04 PH PH12015502708A patent/PH12015502708A1/en unknown
-
2017
- 2017-01-13 US US15/406,128 patent/US10239846B2/en active Active
-
2018
- 2018-06-05 HR HRP20180874TT patent/HRP20180874T1/hr unknown
- 2018-06-12 CY CY20181100611T patent/CY1120338T1/el unknown
-
2019
- 2019-07-09 IL IL267956A patent/IL267956B/en active IP Right Grant
-
2020
- 2020-11-18 NO NO2020039C patent/NO2020039I1/no unknown
- 2020-11-18 HU HUS2000045C patent/HUS2000045I1/hu unknown
- 2020-11-18 FR FR20C1059C patent/FR20C1059I2/fr active Active
- 2020-11-18 LT LTPA2020533C patent/LTC2498610I2/lt unknown
- 2020-11-19 CY CY2020035C patent/CY2020035I2/el unknown
-
2021
- 2021-03-17 HR HRP20210446TT patent/HRP20210446T1/hr unknown
- 2021-03-22 CY CY20211100241T patent/CY1124121T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502708A1 (en) | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | |
| MX2012005559A (es) | Moduladores heterociclicos selectivos del receptor de esfingosina 1 fosfato. | |
| MY160907A (en) | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | |
| WO2012158550A3 (en) | Selective heterocyclic sphingosine 1 phosphate receptor modulators | |
| MX2013004508A (es) | Moduladores del receptor nicotinico alfa-7 para el tratamiento del dolor, un transtorno psicotico, deterioro cognitivo o enfermedad de alzheimer. | |
| MY156381A (en) | Novel modulators of sphingosine phosphate receptors | |
| EA201071245A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс | |
| EA019970B8 (ru) | Производные имидазолидиндиона | |
| MX2020012825A (es) | Compuestos multiciclicos y metodos de uso de los mismos. | |
| WO2009076454A3 (en) | Compounds that modulate intracellular calcium | |
| MY145070A (en) | Imidazolothiazole compounds for the treatment of disease | |
| MY157445A (en) | Compounds that modulate intracellular calcium. | |
| HK1136283A1 (en) | Compounds for the prevention and treatment of cardiovascular diseases | |
| MX2010002712A (es) | Compuestos que modulan calcio intracelular. | |
| WO2010118063A3 (en) | Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use | |
| MX2010007490A (es) | Preparacion de derivados de sulfamida. | |
| MX2011006150A (es) | Compuestos inhibidores de cinasa. | |
| MX2008013196A (es) | 5-amido-2-carboxiamida-indoles. | |
| MX2012004548A (es) | Nuevas composiciones para prevenir y/o tratar transtornos degenerativos del sistema nervioso central. | |
| MX2009011952A (es) | Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr. | |
| MX2009011421A (es) | Derivados de ftalazina e isoquinolina con actividades moduladoras del receptor de la s1p. | |
| WO2011147034A8 (en) | Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof | |
| MX2010001501A (es) | Moduladores de gamma secretasa. | |
| MX2009013197A (es) | Derivados terapeuticos de pirazolonaftiridina. | |
| IL205468A0 (en) | 1, 2, 4, - triazin - 3, 5 - dione compounds for treating disorders that respond to modulation of the dopamine d3 receptor |